ArticleFrontiers in oncology2023
Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Efficacy and safety of durvalumab plus gemcitabine-cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.ESMO open · 2026Article
- Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy.Journal of liver cancer · 2026Review
- Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.Hepatic oncology · 2025Review
- Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma.Frontiers in oncology · 2025Article
- Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab.Internal medicine (Tokyo, Japan) · 2024Article
- Combined hepatocellular cholangiocarcinoma: A clinicopathological update.World journal of hepatology · 2024Review
- Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.Journal of cancer research and clinical oncology · 2024Review
- Current advances and future directions in combined hepatocellular and cholangiocarcinoma.Gastroenterology report · 2024Review
- A Case of First-line Atezolizumab Plus Bevacizumab Use in Recurrence of Combined Hepatocellular Cholangiocarcinoma After Surgical Resection.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established for unresectable cHCC-CCA. Here, we present six cases of cHCC-CCA treated with atezolizumab plus bevacizumab. We observed three partial responses and one stable disease as the best responses; two of these patients were still being treated with atezolizumab plus bevacizumab at the time of reporting (at least five months of treatment), whereas the remaining two patients were unable to continue treatment owing to adverse events. Atezolizumab plus bevacizumab may be an effective treatment for unresectable cHCC-CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.